U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07428707) titled 'Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib' on Feb. 21.
Brief Summary: Background:
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. Pirtobrutinib is a drug approved to treat CLL and SLL after 2 previous treatments. Researchers want to know how this drug affects the immune system in those who have not yet started other treatments for CLL or SLL.
Objective:
To test pirtobrutinib as a first-line treatment for CLL or SLL.
Eligibility:
People aged 18 years and older with untr...